Both vascular endothelial growth factor inhibitors and steroids given intravitreally have demonstrated superior visual acuity (VA) benefits to laser and/or sham for center-involving diabetic macular edema (DME).1

To describe the associations of physical and demographic factors with Goldmann-correlated intraocular pressure (IOPg) and corneal-compensated intraocular pressure (IOPcc) in a British cohort.

In 1911, Paton and Holmes1 published a seminal paper on the pathology of papilledema which established that papilledema was a consequence of intracranial hypertension and not, as previously thought, an inflammatory process.2 Their study also included several incidental observations about folds in papilledema, now occasionally referred to as “Patons folds.” In their words:“as the disc swells lateralwards, it displaces the retina…throwing it into a series of folds which run concentric with the edge of the disc.

To compare the rate of glaucoma structural and functional progression in American and Korean cohorts.

The objective of our study was to investigate preferences of patients with neovascular age-related macular degeneration (nAMD) for different anti-vascular endothelial growth factor (VEGF) treatment schemes.

To describe the design and baseline characteristics of patients enrolled into 2 natural history studies of Stargardt disease (STGD1).